Quantitative proteomics analysis of BMS-214662 effects on CD34 positive cells from chronic myeloid leukaemia patients

Proteomics

Volumn 13, Issue 1, 2013, Pages 153-168

  Balabanov, Stefan ^a   Evans, Caroline A ^b   Abraham, Sheela A ^a   Pellicano, Francesca ^a   Copland, Mhairi ^a   Walker, Michael J ^b   Whetton, Anthony D ^b   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Biomedicine; BMS 214662; Chronic myeloid leukaemia; ITRAQ; Leukaemic stem cells

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; HISTONE; IRON REGULATORY PROTEIN 1;

ARTICLE; CARCINOGENESIS; CD34 SELECTION; CELL FRACTIONATION; CELL NUCLEUS; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOPLASM; CYTOSOL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIGENS, CD34; APOPTOSIS; BENZODIAZEPINES; EVALUATION STUDIES AS TOPIC; FARNESYLTRANSTRANSFERASE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEOME; RAN GTP-BINDING PROTEIN; RNA-BINDING PROTEINS;

EID: 84872378929     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200022     Document Type: Article

References (48)

1. Ren, R., Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 2005, 5, 172-183.
2. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S. et al., Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996, 2, 561-566.
3. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I. et al., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl. J. Med. 2006, 355, 2408-2417.
4. Guilhot, F., Druker, B., Larson, R. A., Gathmann, I. et al., High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009, 94, 1669-1675.
5. Jabbour, E., Kantarjian, H., Jones, D., Talpaz, M. et al., Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006, 20, 1767-1773.
6. Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J. et al., Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. New Engl. J. Med. 2010, 362, 2260-2270.
7. Saglio, G., Kim, D. W., Issaragrisil, S., le Coutre, P. et al., Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New Engl. J. Med. 2010, 362, 2251-2259.
8. Shah, N. P., Tran, C., Lee, F. Y., Chen, P. et al., Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305, 399-401.
9. Fei, F., Stoddart, S., Muschen, M., Kim, Y. M. et al., Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia. Leukemia 2010, 24, 813-820.
10. O'Hare, T., Deininger, M. W., Eide, C. A., Clackson, T. et al., Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin. Cancer Res. 2011, 17, 212-221.
11. Engler, J. R., Frede, A., Saunders, V. A., Zannettino, A. C. et al., Chronic myeloid leukemia CD34 +cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010, 24, 765-770.
12. Burchert, A., Wang, Y., Cai, D., von Bubnoff, N. et al., Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005, 19, 1774-1782.
13. Bixby, D., Talpaz, M., Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology/the Education Program of the American Society of Hematology. Am. Soc. Hematol. Educ. Program 2009, 461-476.
14. Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W. et al., Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006, 107, 4532-4539.
15. Graham, S. M., Jorgensen, H. G., Allan, E., Pearson, C. et al., Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99, 319-325.
16. Schemionek, M., Elling, C., Steidl, U., Baumer, N. et al., BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 2010, 115, 3185-3195.
17. Bellodi, C., Lidonnici, M. R., Hamilton, A., Helgason, G. V. et al., Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J. Clin. Invest. 2009, 119, 1109-1123.
18. Naka, K., Hoshii, T., Muraguchi, T., Tadokoro, Y. et al., TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010, 463, 676-680.
19. Copland, M., Pellicano, F., Richmond, L., Allan, E. K. et al., BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111, 2843-2853.
20. Pellicano, F., Copland, M., Jorgensen, H. G., Mountford, J. et al., BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta. Blood 2009, 114, 4186-4196.
21. Pellicano, F., Simara, P., Sinclair, A., Helgason, G. V. et al., The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 2011, 25, 1159-1167.
22. Peng, X. Q., Wang, F., Geng, X., Zhang, W. M., Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Rev. Proteomics 2009, 6, 551-561.
23. Hanash, S., Taguchi, A., The grand challenge to decipher the cancer proteome. Nat. Rev. Cancer 2010, 10, 652-660.
24. Balabanov, S., Gontarewicz, A., Ziegler, P., Hartmann, U. et al., Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood 2007, 109, 1701-1711.
25. Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T. et al., A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 2010, 143, 1174-1189.
26. Griffiths, S. D., Burthem, J., Unwin, R. D., Holyoake, T. L. et al., The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia. Mol. Biotechnol. 2007, 36, 81-89.
27. Unwin, R. D., Smith, D. L., Blinco, D., Wilson, C. L. et al., Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood 2006, 107, 4687-4694.
28. Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H. et al., PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13, 2129-2141.
29. Guda, C., pTARGET: a web server for predicting protein subcellular localization. Nucleic Acid Res. 2006, 34, W210-W213.
30. Wilson, B. G., Roberts, C. W., SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 2011, 11, 481-492.
31. Allan, E. K., Holyoake, T. L., Craig, A. R., Jorgensen, H. G., Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011, 25, 985-994.
32. Pellicano, F., Simara, P., Sinclair, A., Helgason, G. V. et al., The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells. Leukemia 2011, 25, 1159-1167.
33. Kramer, A., Liashkovich, I., Oberleithner, H., Ludwig, S. et al., Apoptosis leads to a degradation of vital components of active nuclear transport and a dissociation of the nuclear lamina. Proc. Natl. Acad. Scie. USA 2008, 105, 11236-11241.
34. Wu, J., Matunis, M. J., Kraemer, D., Blobel, G. et al., Nup358, a cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous domain, and a leucine-rich region. J. Biol. Chem. 1995, 270, 14209-14213.
35. Grandi, P., Dang, T., Pane, N., Shevchenko, A. et al., Nup93, a vertebrate homologue of yeast Nic96p, forms a complex with a novel 205-kDa protein and is required for correct nuclear pore assembly. Mol. Biol. Cell 1997, 8, 2017-2038.
36. Grote, M., Kubitscheck, U., Reichelt, R., Peters, R., Mapping of nucleoporins to the center of the nuclear pore complex by post-embedding immunogold electron microscopy. J. Cell Sci. 1995, 108(Pt 9), 2963-2972.
37. Shu, W., Chen, Y., Wu, Q., Li, R. et al., Deguelin represses both the expression of nucleophosmin and some nucleoporins: Nup88 and Nup214 in Jurkat cells. Biol. Pharm. Bull. 2008, 31, 27-32.
38. Xu, S., Powers, M. A., Nuclear pore proteins and cancer. Semin. Cell Dev. Biol. 2009, 20, 620-630.
39. Chakraborty, P., Wang, Y., Wei, J. H., van Deursen, J. et al., Nucleoporin levels regulate cell cycle progression and phase-specific gene expression. Dev. Cell 2008, 15, 657-667.
40. Kohler, A., Hurt, E., Gene regulation by nucleoporins and links to cancer. Mol. Cell 2010, 38, 6-15.
41. Lee, C. F., Griffiths, S., Rodriguez-Suarez, E., Pierce, A. et al., Assessment of downstream effectors of BCR/ABL protein tyrosine kinase using combined proteomic approaches. Proteomics 2010, 10, 3321-3342.
42. Liu, Z., Oh, S. M., Okada, M., Liu, X. et al., Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol. Biol. Cell 2009, 20, 757-768.
43. Xia, X., Cheng, A., Lessor, T., Zhang, Y. et al., Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J. Cell. Physiol. 2001, 187, 209-217.
44. Zhang, Y., Woodford, N., Xia, X., Hamburger, A. W., Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acid Res. 2003, 31, 2168-2177.
45. Lessor, T. J., Yoo, J. Y., Xia, X., Woodford, N. et al., Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J. Cell. Physiol. 2000, 183, 321-329.
46. Zhang, Y., Akinmade, D., Hamburger, A. W., Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1. Cancer Lett. 2008, 265, 298-306.
47. Kwon, I. S., Ahn, J. Y., P48 Ebp1 acts as a downstream mediator of Trk signaling in neurons, contributing neuronal differentiation. Neurochem. Int. 2011, 58, 215-223.
48. Squatrito, M., Mancino, M., Donzelli, M., Areces, L. B. et al., EBP1 is a nucleolar growth-regulating protein that is part of pre-ribosomal ribonucleoprotein complexes. Oncogene 2004, 23, 4454-4465.